United States Anti-Inflammatory Drugs Market is expected to reach US$ 198.92 billion by 2031 | Top key players - AbbVie Inc., Pfizer Inc., AstraZeneca.

Market Size and Growth:

The Global Anti-inflammatory Drugs Market size reached US$ 102.72 billion in 2023 and is expected to reach US$ 198.92 billion by 2031, growing at a CAGR of 8.7% during the forecast period 2024-2031. The Market is driven by the rising prevalence of chronic inflammatory diseases and increasing demand for biologics and targeted therapies. According to DataM Intelligence

To Download a Free Sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/anti-inflammatory-drugs-market?sz

The Anti-Inflammatory Drugs Market refers to the global industry focused on the development, production, and sale of medications that reduce inflammation, pain, and swelling caused by various conditions such as arthritis, autoimmune diseases, and allergies. These drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics, playing a crucial role in managing chronic and acute inflammatory disorders.

Industry Recent Developments:

United States:

✅ September 2025: U.S. anti-inflammatory drug manufacturers increased investment in biologic therapies targeting autoimmune and respiratory disorders. This trend is driven by the rising prevalence of these conditions and the growing demand for targeted therapies with fewer side effects.

✅ August 2025: Government initiatives in North America have supported the development and approval of biosimilar drugs, with new biosimilar anti-inflammatory medications entering the market. The focus is particularly strong on alternatives for drugs like Humira and Enbrel to address increasing healthcare costs and patient access.

✅ July 2025: The adoption rate for anti-inflammatory drugs, especially for indications like arthritis and inflammatory bowel disease, continues to grow due to the introduction of innovative, more effective biologic agents. Pharmaceutical companies are also expanding patient and physician awareness campaigns about early intervention and long-term management benefits.

Japan:

✅ September 2025: Japan's anti-inflammatory drugs market saw rising demand for topical NSAID formulations such as gels and creams, driven by its aging population and growing awareness about localized pain management. Healthcare infrastructure expansion has facilitated broader access to these drugs.

✅ August 2025: Japanese regulatory authorities continued to promote generic anti-inflammatory drug use through policy incentives, partnerships, and public campaigns. This was in response to persistent healthcare cost issues and supply reliability needs highlighted in government health ministry discussions.

✅ July 2025: Japanese pharmaceutical companies accelerated collaborations for biosimilar development and distribution, focusing on biosimilar anti-inflammatory biologics to compete globally and meet increasing domestic patient needs. This included strategic mergers and investments to strengthen the supply chain and regulatory compliance.

Get Customization in the report as per your requirements + Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/anti-inflammatory-drugs-market?sz

FDA Approvals & Major regulatory actions (2025):

1. QAMZOVA (meloxicam) - FDA approval (intravenous meloxicam)

✅ What / when: QAMZOVA (meloxicam injection) was approved by the FDA under a 505(b)(2) NDA on April 22, 2025 for management of moderate-to-severe pain (an IV NSAID formulation).

2. XIFYRM (meloxicam) - FDA approval (another IV meloxicam)

✅ What / when: XIFYRMTM (meloxicam injection) received FDA approval in June 2025 for management of moderate-to-severe pain in adults (an IV NSAID). (Note: this is a separate meloxicam injection product; both XIFYRM and QAMZOVA are IV NSAID entries in 2025.)

3. RINVOQ (upadacitinib) - new FDA indication: Giant Cell Arteritis (GCA)

✅ What / when: AbbVie's RINVOQ (a JAK inhibitor) received FDA approval for giant cell arteritis in April 2025, making it the first oral JAK inhibitor approved for GCA - an important expanded inflammatory indication.

4. Other regulatory highlights (EU / EMA / CHMP recs in 2025)

✅ EMA CHMP / EU updates: the EMA published CHMP highlights in 2025 noting positive opinions and indication updates in immunology areas (for example, updated information/indications for some agents used in inflammatory/autoimmune diseases). Specific CHMP highlights in 2025 included medicines with immunology/autoimmune relevance.

Notable 2025 Mergers, Acquisitions and partnerships affecting the inflammation / immunology pipeline:

1. Sanofi → Blueprint Medicines (acquisition completed mid-2025)

✅ Deal: Sanofi announced (June 2) and completed (mid-July 2025) its acquisition of Blueprint Medicines (deal value ~ $9-9.5 billion total), explicitly to expand its immunology / rare immunological disease capabilities (adding Blueprint's approved product for systemic mastocytosis and an immunology pipeline). This strengthens Sanofi's position in immunology / inflammatory rare disease spaces.

2. Johnson & Johnson - acquisitions to boost inflammation capabilities

✅ Examples: J&J made mid-sized purchases in 2025 to secure inflammation assets (e.g., acquisitions/transactions of platform/bispecific companies aimed at IL-13/IL-17/TSLP pathways), reflecting buyer interest in next-gen immunology modalities. (Representative reporting and deal summaries from H1 2025 track these autoimmunity / inflammation-targeted buys.)

3. Gilead & LEO Pharma strategic partnership (stat6 / inflammation programs)

✅ Deal: Gilead entered into a partnership / program acquisition with LEO Pharma in 2025 for preclinical oral STAT6 inhibitors and related degraders, which are aimed at inflammatory skin and respiratory diseases - a clear pipeline bet on inflammation mechanisms.

4. Biogen licensing of anti-inflammatory molecule from Vanqua Bio

✅ Deal: Biogen took a license (upfront + milestone structure) for a preclinical C5aR1 antagonist (anti-inflammatory target) from Vanqua Bio (2025), illustrating pharma licensing activity to add small-molecule anti-inflammatory assets.

Quick implications for the Anti-Inflammatory Drugs Market:

✅ NSAID category-IV formulations re-entered the market in 2025: Two new IV meloxicam approvals (QAMZOVA and XIFYRM) broaden non-opioid perioperative / acute pain options-this can shift short-term hospital analgesia protocols and HCPCS/J-code coverage (CMS already issued HCPCS coding activity in 2025). Expect hospital adoption discussions and formulary evaluations.

✅ JAK inhibitors and immunology remain strategic priorities: RINVOQ's GCA approval is an example of indication expansion for JAK inhibitors beyond classic RA/dermatology indications, increasing the addressable market for established JAKs and raising competition among targeted immunomodulators.

✅ Big-pharma acquisition activity shows pipeline prioritization in immunology: Large deals (Sanofi/Blueprint and multiple strategic buys/partnerships) signal sustained buyer interest in inflammation/immunology R&D - expect continued licensing and M&A to fill mid-late pipelines.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=anti-inflammatory-drugs-market

Major Key Players:

AbbVie Inc.
Johnson & Johnson Services, Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd
AstraZeneca
Novartis AG
Amgen Inc.
GSK plc
Merck & Co., Inc.
Bristol-Myers Squibb Company
Viatris Inc.

Segments Covered in the Anti-Inflammatory Drugs Market:

By Drug Class: Anti-Inflammatory Biologics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), Others.

By Application: Arthritis, Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), Asthma, Tendonitis, Others.

By Route of Administration: Oral, Injection, Inhalation, Topical.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis for Anti-Inflammatory Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Anti-Inflammatory Drugs market?

➠ Who are the global key manufacturers of the Anti-Inflammatory Drugs Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Anti-Inflammatory Drugs market opportunities and threats faced by the vendors in the global Anti-Inflammatory Drugs Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Anti-Inflammatory Drugs market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.